This site is intended for healthcare professionals
A close up image of a microscope
  • Home
  • /
  • Clinical trials
  • /
  • Glomerulonephritis
  • /
  • Evaluate the efficacy and safety of SHR1459 tablet...
Clinical trial

Evaluate the efficacy and safety of SHR1459 tablets in patients with primary membranous nephropathy

Read time: 1 mins
Last updated:31st Jul 2024
Status: Active, not recruiting
Identifier: NCT05136456
Evaluate the efficacy and safety of SHR1459 tablets in patients with primary membranous nephropathy


ClinicalTrials.gov ID: NCT05136456
Sponsor: Reistone Biopharma Company Limited
Information provided by: Reistone Biopharma Company Limited (Responsible Party)
Last Update Posted: 2023-09-05

Brief Summary:

The purpose of this study is to evaluate the efficacy and safety of SHR1459 tablets in patients with primary membranous nephropathy.

Detailed Description:
This study is a phase II study to evaluate the efficacy and safety of SHR1459 tablets in patients with primary membranous nephropathy.

Official Title:
A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR1459 Tablets in the Treatment of Primary Membranous Nephropathy (PMN)

Intervention / Treatment: 
- Drug: SHR1459 Low Dose
- Drug: SHR1459 High Dose
- Drug: Placebo

Category Value
Study Start (Actual)
2021-12-15
Primary Completion (Estimated)
2023-08-28
Study Completion (Estimated)
2024-03-11
Enrollment (Estimated) 61
Study Type Interventional
Phase Phase 2
Other Study ID Numbers
RSB20926

View full details